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INTRODUCI'ION
ff or over 40 years intravesical BCG has been the gold J standard treatment for intennediate-and high-risk non-muscle-invasive bladder cancer (NMIBC) after transurethral bladder resection.Pl BCG is an attenuated live strain of Mycobacterium bm is, and although its mechanism of action is not completely understood, it is believed that the treatment works through an immune response and a direct tumor response. [21 Adjuvant BCG is highly effective in reducing the risk of recurrence of high-grade NMIBC by up to 70% compared with transurethral resection.!31 For carcinoma in situ (CIS), BCG has been shown to generate a complete response in up to 70%--90% of cases_[ 4 J Minor toxic reactions such as urinaiy frequency, urgency, dysuria, and hematuria have been reported in 27%-90% of the patientsYJ Granulomatous complications are very uncommon and include entities such as prostatitis, epididymo-orchitis, cystitis, pyelonephritis, and abscessesYl The incidence of significant renal complications is significantly less and varies from 0.2% to 2% with renal granulomatosis occmTing in 0.1 % of treated patientsYl We report a rare case of renal granulomas seen on imaging post intravesical BCG therapy for NMIBC . Figure 2a and b]. The differential included infection or inflammation. PrimaIY renal malignancies such as renal cell carcinoma and mothelial cell carcinoma and infiltrative masses such as lymphoma continued to be the main suspicions, and a CT-guided biopsy was recommended for histological confimrntion [ Figure 3a ]. Histopathology confirmed marked chronic inflammation and necrotizing granulomas without evidence for The incidence of renal toxicity from BCG is anywhere from 0.2% to 2% with the development of a granulomatous renal mass occurring in <0.1 % of patients.r 5 .s1 In some rep01ts, renal disease presented as pyelonephtitis after the third or fourth instillation doses. It can also present as flank pain or urinaiy frequency.rs1 Other patients such as in our case present with features of renal mass.rs1 It has been hypothesized that renal affliction by BCG therapy may be related to vesicoureteral reflux that commonly occurs after transuretht·al resection of bladder tmnor.r 9 
1
Imaging of post intravesical therapy, BCG granulomas can present as enhancing lesions on CECT scans)5J Renal manifestations may include pyelonephtitis or abscesses with a segmental disu·ibution and pe1fuepht·ic su·anding) 8 1 Some may even mimic expansile masses or present as multiple hypodense lesions with the kidney)5J A "central unaffected calyx sign" has been described that shows BCG granulomatosis as a solid mass in the kidney with a normal calyx centrally.P 0 1 The main differential considerations would, however, include primaiy renal neoplasms such as renal cell cai·cinoma or infilu·ative conditions such as lymphoma or leukemia Imaging can be quite inconclusive in the vast majotity of the cases of renal granulomatosis such as in our case especially given the extremely low incidence of the condition. It would be pmdent to obtain histological confi1mation by image-guided percutaneous biopsy if there is no convincing improvement on subsequent follow-up imaging. Once confirmed, renal granulomas may be u·eated with rifainpin and isoniazid for 3-6 months.rs1 Sometimes, no treatment is undertaken and these granulomas tend resolve spontaneously as m our case. rs1 CONCLUSION BCG is the gold standai·d therapy for NMIBC. Although it is usually well tolerated, a small number of patients can have systemic side effects. As renal granulomas though can present in a vatiety of different ways, it is essential to have high clinical suspicion to consider post BCG treatment reaction as a possible differential diagnosis. This case demonstrates the pmdence of strict follow-up imaging so that prompt therapy can be initiated when necessaiy while the renal lesions are still asymptomatic. Although extremely rare, recognition of imaging findings of renal granulomas with an appropriate history is imp01tant to distinguish it from a primaiy renal or metastatic neoplastic process to avoid unnecessaiy surgical procedures and to prese1ve renal parenchyma.
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